The translocation t(4; 11) is the most common finding in infants with ALL, and is a poor prognostic indicator and is a significant indepent risk factor. The patient with the t(4; 11) require more intensiva quimiotherapy. Recent advances in understanding the alterations in the function of the fusion genes as compared with normal genes provide insights regarding new therapeutic strategies, wich should lead to improve clinical responsos with less toxicity.